Sigilon Therapeutics Secures $80.3M Series B Back to HomeCAMBRIDGE, MA, Sigilon Therapeutics today announced that it has completed a $80.3 million Series B financing.

Sigilon Therapeutics, a biotechnology company developing functional cures for patients with chronic diseases through its Shielded Living Therapeutics platform, today announced that it has completed a $80.3 million Series B financing.

"Sigilon is driven to liberate patients from the fear of living with serious chronic diseases, and from alternative therapeutic approaches," said Rogerio Vivaldi, M.D., President and CEO of Sigilon.

"Our Shielded Living Therapeutics platform is designed to give patients who have chronic diseases a convenient, safe, long-term therapeutic benefit.

About Sigilon TherapeuticsSigilon Therapeutics is developing functional cures for chronic diseases through its Shielded Living Therapeutics™ platform. | To read full story, visit https://startuparound.com/read/1584489607.0408206/Sigilon-Therapeutics-Secures-$80.3M-Series-B?ref=audio_experience